An open label, balanced, randomised, four-treatment, four-period, four-sequence, single oral
dose, crossover Pharmacokinetics study of WD-1603 carbidopa/levodopa extended-release tablets
in normal, healthy, adult human subjects under fed conditions. A single oral dose of (either
Treatment A or B or C or D) carbidopa/levodopa extended release tablets will be administered
to each subject within 5 minutes after completion of standardized vegetarian breakfast under
fed condition in each period as per randomization schedule.
Phase:
Phase 1
Details
Lead Sponsor:
Hong Kong WD Pharmaceutical Co., Limited
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa